Meet our new competitor in the race for a hep b therapeutic.
“”The Company believes that now is the appropriate time to maximise the CoSensia opportunity in China and globally, and at the same time advance its Hepatitis B virus (HBV) therapeutic program to the clinical proof of concept stage.””
Both companies competing for the billion dollar Hep b market and Benitec former boss Peter French now a board member with the Chinese entity.
http://www.biomics.com/about_board.html
Add to My Watchlist
What is My Watchlist?